CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression

CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression

Abstract Metastatic prostate cancer (PCa) poses a significant therapeutic challenge with high mortality rates. Utilizing CRISPR-Cas9 in vivo, we target five potential tumor suppressor genes (Pten, Trp53, Rb1, Stk11, and RnaseL) in the mouse prostate, reaching humane endpoint after eight weeks withou...

Full description

Bibliographic Details
Main Authors: Huiqiang Cai, Bin Zhang, Johanne Ahrenfeldt, Justin V. Joseph, Maria Riedel, Zongliang Gao, Sofie K. Thomsen, Ditte S. Christensen, Rasmus O. Bak, Henrik Hager, Mikkel H. Vendelbo, Xin Gao, Nicolai Birkbak, Martin K. Thomsen
Format: Article
Language:English
Published: Nature Portfolio 2024-03-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-46370-0

Similar Items

Similar Items